| 價格 | 詢價 |
| 包裝 | 1支 |
| 最小起訂量 | 1支 |
| 發(fā)貨地 | 湖北 |
| 更新日期 | 2026-07-30 |
| 中文名稱:Pumilio 2 (18V6)兔單抗 | 英文名稱:Pumilio 2 (18V6) Rabbit Monoclonal Antibody |
| 品牌: EnkiLife | 產(chǎn)地: 中國 |
| 產(chǎn)品類別: 抗體 | |
| 是否進口: 否 | 用途: 科研 |
產(chǎn)品概述
產(chǎn)品性能
免疫原
產(chǎn)品應用
研究背景
Sequence-specific RNA-binding protein that regulates translation and mRNA stability by binding the 3'-UTR of mRNA targets. Its interactions and tissue specificity suggest that it may be required to support proliferation and self-renewal of stem cells by regulating the translation of key transcripts. Sequence-specific RNA-binding protein that acts as a post- transcriptional repressor by binding the 3'-UTR of mRNA targets. Binds to an RNA consensus sequence, the Pumilio Response Element (PRE), 5'- UGUANAUA-3', that is related to the Nanos Response Element (NRE) (, PubMed:21397187). Mediates post-transcriptional repression of transcripts via different mechanisms: acts via direct recruitment of the CCR4-POP2-NOT deadenylase leading to translational inhibition and mRNA degradation (PubMed:22955276). Also mediates deadenylation- independent repression by promoting accessibility of miRNAs (PubMed:18776931, PubMed:22345517). Acts as a post-transcriptional repressor of E2F3 mRNAs by binding to its 3'-UTR and facilitating miRNA regulation (PubMed:22345517). Plays a role in cytoplasmic sensing of viral infection (PubMed:25340845). Represses a program of genes necessary to maintain genomic stability such as key mitotic, DNA repair and DNA replication factors. Its ability to repress those target mRNAs is regulated by the lncRNA NORAD (non-coding RNA activated by DNA damage) which, due to its high abundance and multitude of PUMILIO binding sites, is able to sequester a significant fraction of PUM1 and PUM2 in the cytoplasm (PubMed:26724866). May regulate DCUN1D3 mRNA levels (PubMed:25349211). May support proliferation and self-renewal of stem cells. Binds specifically to miRNA MIR199A precursor, with PUM1, regulates miRNA MIR199A expression at a postranscriptional level (PubMed:28431233).
研究領(lǐng)域
| 成立日期 | 2024-08-02 (3年) | 注冊資本 | 271萬人民幣 |
| 員工人數(shù) | 10-50人 | 年營業(yè)額 | ¥ 100萬-300萬 |
| 主營行業(yè) | 生化試劑,抗體,細胞培養(yǎng),癌癥研究,細胞生物學 | 經(jīng)營模式 | 工廠,試劑,定制,服務 |
| 產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
|---|---|---|---|---|
| 詢價 |
VIP5年
|
上海優(yōu)寧維生物科技股份有限公司
|
2026-08-04 | |
| 詢價 |
碧云天生物技術(shù)有限公司
|
2026-07-28 | ||
| 詢價 |
北京百奧萊博科技有限公司
|
2026-07-28 |